Skip to content
OpenCapital
Earnings
Screener
Charts
Portfolio
Pricing
Connect your AI
Get started
Toggle navigation menu
Stocks
BioCryst Pharmaceuticals
Business Segments
Products & Services
Revenue percentage
Revenue percentage
BioCryst Pharmaceuticals
·
Products & Services
·
2 segments
·
Rolls up to
Concentration Risk %
Breakdown
Segments
ORLADEYO
View metric
Product sales, net
View metric
Quarterly
Annual
TTM
Segment
Q1 '25
Q2 '25
Q3 '25
Q1 '26
ORLADEYO
85%
86%
88%
93%
Total
—
—
—
—
Product sales, net is derived from annual filings.
